|
|
|
Volumn 61, Issue 12, 2012, Pages 744-746
|
|
Hepatitis C: New CDC screening recommendations
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
BOCEPREVIR;
PEGINTERFERON;
RIBAVIRIN;
TELAPREVIR;
VIRUS ANTIBODY;
ARTICLE;
BIOPSY;
BLOOD TRANSFUSION;
CANCER INCIDENCE;
CLINICAL TRIAL (TOPIC);
DECOMPENSATED LIVER CIRRHOSIS;
DRUG WITHDRAWAL;
FIBROSIS;
GENOTYPE;
HEALTH CARE PERSONNEL;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGH RISK BEHAVIOR;
HUMAN;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
LIVER DISEASE;
MEDICAL RESEARCH;
MORBIDITY;
MORTALITY;
OBSERVATIONAL STUDY;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PREVALENCE;
PUBLIC HEALTH SERVICE;
RISK;
RISK FACTOR;
SCREENING;
UNSPECIFIED SIDE EFFECT;
VASCULARIZATION;
VIRAL CLEARANCE;
VIRUS TRANSMISSION;
HEALTH CARE PLANNING;
INCIDENCE;
LIVER TUMOR;
MASS SCREENING;
METHODOLOGY;
ORGANIZATION AND MANAGEMENT;
TREATMENT OUTCOME;
UNITED STATES;
ANTIVIRAL AGENTS;
CARCINOMA, HEPATOCELLULAR;
CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.);
HEALTH PLANNING GUIDELINES;
HEPATITIS C;
HUMANS;
INCIDENCE;
LIVER NEOPLASMS;
MASS SCREENING;
OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);
PREVALENCE;
RISK FACTORS;
UNITED STATES;
MLCS;
MLOWN;
|
|
EID: 84874999584
PISSN: 00943509
EISSN: 15337294
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (5)
|
